Clear Harbor Asset Management LLC lowered its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 24.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,582 shares of the medical research company’s stock after selling 2,123 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in Amgen were worth $2,383,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of the business. Norges Bank purchased a new stake in Amgen in the 4th quarter valued at approximately $2,164,162,000. Capital World Investors grew its holdings in Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after buying an additional 4,302,237 shares during the last quarter. BlackRock Inc. increased its position in Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after buying an additional 2,261,544 shares in the last quarter. State Street Corp increased its position in Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after buying an additional 1,287,310 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.
Amgen Stock Performance
Amgen stock opened at $439.33 on Friday. The firm has a market capitalization of $237.52 billion, a P/E ratio of 27.30, a PEG ratio of 3.17 and a beta of 0.41. The stock has a fifty day moving average price of $379.03 and a 200 day moving average price of $361.95. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $443.20. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.
Amgen Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio is presently 62.65%.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the company. Barclays increased their price objective on Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. Piper Sandler boosted their target price on shares of Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a research note on Thursday. Wells Fargo & Company upped their target price on shares of Amgen from $390.00 to $400.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. Guggenheim raised their price target on shares of Amgen from $343.00 to $388.00 and gave the stock a “neutral” rating in a research note on Monday, August 10th. Finally, Bank of America lifted their price target on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $380.43.
Check Out Our Latest Stock Report on Amgen
Key Stories Impacting Amgen
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Solid operating performance and dividend support the valuation. Amgen’s second-quarter results exceeded expectations, with revenue rising year over year and earnings per share topping consensus. Continued growth and the company’s dividend are helping support investor confidence. Amgen stock holds close to record high as Q2 2026 growth and dividend support valuation
- Positive Sentiment: Analysts raised their outlook. Argus increased its price target to $460 from $375 while maintaining a Buy rating, citing the latest quarterly performance and progress across Amgen’s drug portfolio. Separate reports also highlighted favorable forecasts from Mizuho and Cantor Fitzgerald, reinforcing the bullish analyst sentiment. Amgen gets a fresh target
- Positive Sentiment: Tarlatamab development advanced. Amgen’s Phase 3 DeLLphi-315 study is evaluating a subcutaneous injection of tarlatamab against the current intravenous infusion approach in lung cancer. A successful shot formulation could improve convenience and broaden the commercial potential of the drug. Amgen advances tarlatamab shot versus infusion in Phase 3 lung cancer study
- Positive Sentiment: Trading momentum and options activity were unusually strong. Amgen was identified as a momentum stock after a substantial recent share-price rally, while call-option volume surged well above typical levels, suggesting increased bullish positioning.
- Neutral Sentiment: Valuation is becoming a consideration. With the stock near its recent high and analysts raising targets, some commentary questioned whether much of the favorable news is already reflected in the share price, which could limit near-term upside.
Insider Activity at Amgen
In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 6,222 shares of company stock worth $2,540,926 over the last three months. Corporate insiders own 0.85% of the company’s stock.
Amgen Company Profile
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Read More
- Five stocks we like better than Amgen
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
